Read More

Celularity Says That Its Expected Net Sales For Q1 2024 Are Trending Ahead Of The Expectations It Announced In February For Its Advanced Biomaterial Products And Biobanking Businesses; Implements Planned 2024 SG&A Reductions And Manufacturing Ramp For…

Expects the First Quarter of 2024 will be the 4th consecutive quarter of both sequential and quarter-on-quarter net sales growth Implements plan to reduce 2024 selling, general & administrative expenses

CELU

Read More

Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated As A Carrier Of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells In The Treatment Of Severe Ocular Surface Disease

-Highlights potential uses of Celularity biomaterials in regenerative medicine applications that combine stem cells and biomaterial scaffolds for use in constructing tissues and for cell delivery   -Poster

CELU